Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: The Framingham Offspring Study

Annals of Internal Medicine

Volumn 128, Issue 7, 1998, Pages 524-533

  Meigs, James B ^a   Nathan, David M ^a   Wilson, Peter W F ^b   Cupples, L Adrienne ^c   Singer, Daniel E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032055822     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-7-199804010-00002     Document Type: Article

References (68)

1. World Health Organization. WHO Expert Committee on Diabetes Mellitus: Second Report. Geneva: World Health Organization; 1980.
2. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes. 1979;28:1039-57.
3. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes. 1987;36:523-34.
4. Stern MP, Rosenthal M, Haffner SM. A new concept of impaired glucose tolerance. Relation to cardiovascular risk. Arteriosclerosis. 1985;5:311-4.
5. Jarrett RJ. Do we need IGT? Diabet Med. 1987;4:544-5.
6. Yudkin JS, Alberti KG, McLarty DG, Swai AB. Impaired glucose tolerance BMJ. 1990;301:397-402.
7. Olefsky JM, Reaven GM. Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes. 1974;23: 449-53.
8. Mooy JM, Gootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia. 1996;39:298-305.
9. Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford Survey (1962-1972): glucose tolerance and diabetes. Diabetologia. 1982;22: 73-8.
10. Riccardi G, Vaccaro O, Rivellese A, Pignalosa S, Tutino L, Mancini M. Reproducibility of the new diagnostic criteria for impaired glucose tolerance. Am J Epidemiol. 1985;121:422-9.
11. Stern MP, Valdez RA, Haffner SM, Mitchell BD, Hazuda HP. Stability over time of the modern diagnostic criteria for type II diabetes. Diabetes Care. 1993;16:978-83.
12. O'Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. Diabetes. 1964;13:278-85.
13. Jarrett RJ, Keen H, McCartney P. The Whitehall Study: ten year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. Diabet Med. 1984;1:279-83.
14. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med. 1988;319:1500-6.
15. Edelstein SL, Knowler WC, Bain RP, Barrett-Connor EL, Dowse GK, Haffner SM, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701-10.
16. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Bennett PH. Transient impaired glucose tolerance in Pima Indians: is it important? BMJ. 1988;297: 1438-41.
17. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980;1: 1373-6.
18. Jarrett RJ, McCartney P, Keen H. The Bedford Survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia. 1982;22:79-84.
19. Fujimoto WY, Leonetti DL, Kinyoun JL, Shuman WP, Stolov WC, Wahl PW. Prevalence of complications among second-generation Japanese-American men with diabetes, impaired glucose tolerance, or normal glucose tolerance. Diabetes. 1987;36:730-9.
20. Rewers M, Shetterly SM, Baxter J, Marshall JA, Hamman RF. Prevalence of coronary heart disease in subjects with normal and impaired glucose tolerance and non-insulin dependent diabetes mellitus in a biethnic Colorado population. The San Luis Valley Diabetes Study. Am J Epidemiol. 1992;135: 1321-30.
21. Wingard DL, Barrett-Connor E. Family history of diabetes and cardiovascular disease risk factors and mortality among euglycemic, borderline hyperglycemic, and diabetic adults. Am J Epidemiol. 1987;125:948-58.
22. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care. 1989;12:464-74.
23. Burchfiel CM, Hamman RF, Marshall JA, Baxter J, Kahn LB, Amirani JJ. Cardiovascular risk factors and impaired glucose tolerance: the San Luis Valley diabetes study. Am J Epidemiol. 1990;131:57-70.
24. Rodriguez BL, Curb JD, Burchfiel CM, Huang B, Sharp DS, Lu GY, et al. Impaired glucose tolerance, diabetes, and cardiovascular disease risk factor profiles in the elderly. The Honolulu Heart Program. Diabetes Care. 1996;19:587-90.
25. Mykkanen L, Laakso M, Pyorala K. Asymptomatic hyperglycemia and atherosclerotic vascular disease in the elderly. Diabetes Care. 1992;15:1020-30.
26. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
27. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715-22.
28. Everhart J, Knowler WC, Bennett PH. Incidence and risk factors for non-insulin-dependent diabetes mellitus. In: National Diabetes Data Group. Diabetes in America. Bethesda, MD: US Dept of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases; 1985:IV-1. NIH publication no. 85-1468.
29. Barrett-Connor E, Wingard DL, Criqui MH, Suarez L. Is borderline fasting hyperglycemia a risk factor for cardiovascular death? J Chron Dis. 1984;37:773-9.
30. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987;36:689-92.
31. Feskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular diseases: the Zutphen Study. J Clin Epidemiol. 1992;45:1327-34.
32. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes. 1992;41:202-8.
33. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-8.
34. Stokes JI 3d, Kannel WB, Wolf PA, D'Agostino RB. Cupples LA. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study - 30 years of follow-up. Hypertension. 1989;13(5 Suppl):l13-8.
35. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153:598-615.
36. Gerstein HC, Yusuf S. Dysglycemia and risk of cardiovascular disease. Lancet. 1996;347:949-50.
37. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol. 1979;110:281-90.
38. Health implications of obesity. National Institutes of Health Consensus Development Conference Statement. Ann Intern Med. 1985;103(6 Pt 2):1073-7.
39. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153: 154-83.
40. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959-65.
41. Anderson RL, Hamman RF, Savage PJ, Saad MF, Laws A, Kades WW, et al. Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests. The Insulin Resistance Atherosclerosis Study. Am J Epidemiol. 1995;142:724-32.
42. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984;310:341-6.
43. Meigs JB, Nathan DM, Cupples LA, Wilson PW, Singer DE. Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. J Clin Epidemiol. 1996;49:411-7.
44. Nathan DM. Labile glycosylated hemoglobin contributes to hemoglobin A1 as measured by liquid chromatography or electrophoresis. Clin Chem. 1981; 27:1261-3.
45. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86.
46. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 1987;166:1-8.
47. + precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28:1379-88.
48. Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982;23:1206-23.
49. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
50. SAS/STAT User's Guide. Version 6, 4th ed. Cary, NC: SAS Institute; 1989.
51. Kannel WB, Sorlie P. Some health benefits of physical activity. The Framingham Study. Arch Intern Med. 1979;139:857-61.
52. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley-Interscience; 1989.
53. Laakso M, Barrett-Conner E. Asymptomatic hyperglycemia is associated with lipid and lipoprotein changes favoring atherosclerosis. Arteriosclerosis. 1989;9:665-72.
54. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-97.
55. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83-8.
56. Wilson PW, McGee DL, Kannel WB. Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: The Framingham Study. Am J Epidemiol. 1981;114:697-704.
57. Knowler WC, Pettitt DJ, Savage PJ, Bennett PH. Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes. Am J Epidemiol. 1981;113:144-56.
58. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, et al. Weight, weight change, and coronary heart disease in women. Risk within the "normal" weight range. JAMA. 1995;273:461-5.
59. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326:22-9.
60. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-94.
61. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, de Gregorio M, et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 1991;324:733-9.
62. Mitchell BD, Stern MP, Haffner SM, Hazuda HP, Patterson JK. Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites. San Antonio Heart Study. Am J Epidemiol. 1990;131:423-33.
63. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is. . . or is it? Lancet. 1997;350 Suppl 1:S14-9.
64. Eastman RC, Cowie CC, Harris MI. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk [Editorial]. Diabetes Care. 1997;20:127-8.
65. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20:735-44.
66. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2d ed. Baltimore: Williams & Wilkins; 1996.
67. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276:1886-92.
68. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-20.